Pharmacokinetics of high-dose i.v. alizapride in prevention of cisplatin-induced emesis.
Alizapride is a new antidopaminergic-related benzamide with specific antiemetic properties. Pharmacokinetics at a high repetitive dose (16 mg/kg) shows a biexponential plasma decay with T1/2 alpha of 8.33 +/- 2.47 min and T1/2 beta 2.8 +/- 0.7 hr. Large Vdss and high total body clearance are apparent. We demonstrate an increase in drug exposure during the first 6 hr after CDDP infusion by shortening the interval between injections. We conclude that the rate of infusion of alizapride could be important in the efficacy of the drug.
Canal
P
P
Groupe de Recherches Carcinologiques, Centre Claudius Regaud, Toulouse, France.
Roche
H
H
Pasquier
M
M
Bugat
R
R
Berg
D
D
Soula
G
G
Carton
M
M
D000932:Antiemetics / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D011759:Pyrrolidines; C033968:alizapride; D002945:Cisplatin